PMID- 29995828
OWN - NLM
STAT- MEDLINE
DCOM- 20180727
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 28
DP  - 2018 Jul
TI  - Efficacy and tolerability of fluvoxamine in adults with social anxiety disorder: 
      A meta-analysis.
PG  - e11547
LID - 10.1097/MD.0000000000011547 [doi]
LID - e11547
AB  - BACKGROUND: No meta-analysis for estimating the comprehensive efficacy and 
      tolerability of fluvoxamine in patients with social anxiety disorder (SAD) has 
      been published. OBJECTIVE: To investigate the efficacy and tolerability of 
      fluvoxamine in adults with SAD, trials meeting the following criteria were 
      identified: population: >/=18 years of age with a diagnosis of SAD; intervention: 
      fluvoxamine; study design: placebo-controlled randomized controlled trials 
      (RCTs); outcomes: efficacy and tolerability outcomes. METHODS: We conducted a 
      comprehensive search of PubMed, Embase, Cochrane Central Register of Controlled 
      Trials, Web of Science, and ClinicalTrials.gov for RCTs on January 3, 2018. 
      Review Manager 5.3 and Stata Version 12.0 software were used for all statistical 
      analyses. Mean differences (MDs) with 95% confidence intervals (CIs) were 
      calculated for continuous variables, and odds ratios (ORs) with 95% CIs were 
      calculated for dichotomous variables. Cochrane Collaboration's risk of bias tool 
      was used to assess the likelihood of risk of bias. Efficacy was assessed by mean 
      changes in the Liebowitz Social Anxiety scale (LSAS) total score and the Clinical 
      Global Impression Severity of Illness (CGI-S) score as well as the response rate. 
      Tolerability was mainly assessed by the discontinuation rate due to adverse 
      events (AEs) and the incidence of most frequent treatment-emergent AEs (TEAEs). 
      RESULTS: This meta-analysis included 5 RCTs. Mean changes in LSAS total and CGI-S 
      scores were both significantly greater in patients treated with fluvoxamine than 
      those treated with placebo (LSAS: MD = 11.90, 95% CI = 8.09-15.71, P < .001; 
      CGI-S: MD = 0.52, 95% CI = 0.33-0.72, P < .001). Response rate was higher in 
      fluvoxamine group as compared with placebo (OR = 1.71, 95% CI = 1.30-2.24, 
      P < .001). Additionally, mean change in the Sheehan disability scale score was 
      significantly greater in fluvoxamine group than placebo group (OR = 2.11, 95% 
      CI = 1.03-3.18, P < .001). The discontinuation rate due to AEs was higher in 
      patients that received fluvoxamine compared to those received placebo (OR = 5.99, 
      95% CI = 2.24-15.99, P < .001), as was the incidence of overall TEAEs (any AE) 
      (OR = 2.66, 95% CI = 1.77-4.02, P < .001). However, the incidence of serious AEs 
      was not significantly different between the 2 groups (OR = 0.99, 95% 
      CI = 0.25-3.89, P = .99). CONCLUSION: Fluvoxamine was found to be effective in 
      adult patients with SAD, with acceptable tolerability.
FAU - Liu, Xue
AU  - Liu X
AD  - Department of Gynaecology and Obstetrics, China-Japan Union Hospital of Jilin 
      University Department of Neurology, Neuroscience Centre Department of 
      Stomatology, The First Teaching Hospital of Jilin University Department of 
      Gastrointestinal Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin 
      University, Changchun, China.
FAU - Li, Xinyuan
AU  - Li X
FAU - Zhang, Congxiao
AU  - Zhang C
FAU - Sun, Mingze
AU  - Sun M
FAU - Sun, Ziqian
AU  - Sun Z
FAU - Xu, Yanan
AU  - Xu Y
FAU - Tian, Xiujuan
AU  - Tian X
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Anti-Anxiety Agents)
RN  - O4L1XPO44W (Fluvoxamine)
SB  - IM
MH  - Adult
MH  - Anti-Anxiety Agents/adverse effects/*therapeutic use
MH  - Female
MH  - Fluvoxamine/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phobia, Social/*drug therapy
MH  - Severity of Illness Index
MH  - Treatment Outcome
PMC - PMC6076099
EDAT- 2018/07/12 06:00
MHDA- 2018/07/28 06:00
PMCR- 2018/07/13
CRDT- 2018/07/12 06:00
PHST- 2018/07/12 06:00 [entrez]
PHST- 2018/07/12 06:00 [pubmed]
PHST- 2018/07/28 06:00 [medline]
PHST- 2018/07/13 00:00 [pmc-release]
AID - 00005792-201807130-00079 [pii]
AID - MD-D-18-02048 [pii]
AID - 10.1097/MD.0000000000011547 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Jul;97(28):e11547. doi: 10.1097/MD.0000000000011547.